OMERS ADMINISTRATION Corp Makes New Investment in United Therapeutics Corporation $UTHR

OMERS ADMINISTRATION Corp purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,665 shares of the biotechnology company’s stock, valued at approximately $4,153,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Geneos Wealth Management Inc. grew its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the period. Jump Financial LLC bought a new position in United Therapeutics during the second quarter worth about $277,000. Cerity Partners LLC lifted its holdings in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia lifted its holdings in United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 105 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Up 1.1%

Shares of NASDAQ UTHR opened at $518.53 on Wednesday. The firm has a market cap of $22.24 billion, a PE ratio of 18.55, a PEG ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The company has a fifty day moving average price of $531.75 and a 200 day moving average price of $538.30.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the business posted $6.41 EPS. Equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on UTHR. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada decreased their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total value of $5,185,385.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,113,210.79. This trade represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 434,075 shares of company stock valued at $233,340,010. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.